Brokers Set Expectations for Clorox’s Q2 Earnings (NYSE:CLX)

The Clorox Company (NYSE:CLX) – Investment analysts at Zacks Research cut their Q2 2025 earnings estimates for Clorox in a research report issued on Wednesday, November 13th. Zacks Research analyst R. Lohia now expects that the company will post earnings per share of $1.39 for the quarter, down from their previous forecast of $1.56. The consensus estimate for Clorox’s current full-year earnings is $6.85 per share. Zacks Research also issued estimates for Clorox’s Q3 2025 earnings at $1.68 EPS, Q4 2025 earnings at $1.92 EPS, FY2025 earnings at $6.85 EPS, Q2 2026 earnings at $1.69 EPS, Q3 2026 earnings at $1.83 EPS, Q4 2026 earnings at $1.90 EPS, FY2026 earnings at $7.17 EPS, Q1 2027 earnings at $1.81 EPS and FY2027 earnings at $7.56 EPS.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.50. The company had revenue of $1.76 billion for the quarter, compared to analyst estimates of $1.64 billion. Clorox had a return on equity of 316.08% and a net margin of 4.78%. The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.49 EPS.

Several other analysts have also recently issued reports on CLX. TD Cowen upgraded Clorox from a “sell” rating to a “hold” rating and upped their target price for the company from $155.00 to $170.00 in a report on Wednesday, November 6th. Evercore ISI dropped their price objective on shares of Clorox from $140.00 to $139.00 and set an “underperform” rating for the company in a report on Monday, October 14th. Jefferies Financial Group raised shares of Clorox from a “hold” rating to a “buy” rating and lifted their target price for the stock from $174.00 to $187.00 in a research note on Tuesday, October 1st. Barclays boosted their target price on shares of Clorox from $137.00 to $139.00 and gave the company an “underweight” rating in a report on Friday, November 1st. Finally, DA Davidson raised their price target on shares of Clorox from $153.00 to $171.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Five analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $155.00.

Clorox Trading Up 1.1 %

Shares of Clorox stock opened at $167.64 on Friday. The company has a debt-to-equity ratio of 11.08, a current ratio of 1.00 and a quick ratio of 0.62. The stock’s 50 day simple moving average is $162.45 and its 200-day simple moving average is $147.47. The stock has a market cap of $20.75 billion, a P/E ratio of 58.43, a P/E/G ratio of 3.06 and a beta of 0.41. Clorox has a 1-year low of $127.60 and a 1-year high of $169.09.

Institutional Investors Weigh In On Clorox

Several institutional investors have recently added to or reduced their stakes in CLX. Prospera Private Wealth LLC acquired a new position in Clorox during the third quarter worth approximately $27,000. Innealta Capital LLC purchased a new stake in Clorox in the 2nd quarter valued at $30,000. Trifecta Capital Advisors LLC boosted its stake in Clorox by 139.8% during the 2nd quarter. Trifecta Capital Advisors LLC now owns 223 shares of the company’s stock worth $30,000 after purchasing an additional 130 shares during the period. Continuum Advisory LLC grew its position in Clorox by 300.0% during the 3rd quarter. Continuum Advisory LLC now owns 184 shares of the company’s stock worth $30,000 after purchasing an additional 138 shares during the last quarter. Finally, First Foundation Advisors acquired a new position in Clorox in the first quarter valued at $31,000. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Insider Buying and Selling at Clorox

In other news, EVP Angela C. Hilt sold 1,733 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $165.52, for a total transaction of $286,846.16. Following the completion of the transaction, the executive vice president now directly owns 13,471 shares of the company’s stock, valued at approximately $2,229,719.92. This represents a 11.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.57% of the company’s stock.

Clorox Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, November 7th. Shareholders of record on Wednesday, October 23rd were issued a dividend of $1.22 per share. This represents a $4.88 annualized dividend and a yield of 2.91%. The ex-dividend date was Wednesday, October 23rd. Clorox’s dividend payout ratio (DPR) is presently 170.04%.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.